Double signal stimulation was required for full recovery of the autologous tumor-killing effect of effusion-associated lymphocytes.

STUDY OBJECTIVES To determine the different effects of interleukin (IL)-2, IL-4, IL-7, IL-10, IL-12, and/or T-cell receptor (TCR)-CD3 engagement in recovering the functions of cytotoxic T lymphocytes (CTL) from malignant effusion. SETTING National teaching hospital. MATERIALS AND METHODS Effusion-associated lymphocytes (EAL) were isolated from 35 malignant pleural effusions. Interferon (IFN)-gamma production, proliferative response, and cytolytic activity of the cultured EAL against autologous tumors and K-562 cells were measured. RESULTS It was found that EAL had a significantly depressed function. Stimulation with two signals, including IL-2 plus IL-7, IL-2 plus IL-12, or IL-2 plus TCR-CD3 engagement, could fully restore the functions of EAL, including IFN-gamma production, proliferative response, and a specific increase in cytolytic activity against autologous tumor cells. IL-4 and IL-10, whether or not in combination with IL-2, did not augment the function of EAL, and even depressed it in some cases. The lymphocyte-depletion test showed that most of the recovered functions were from CD8(+) CTL. CONCLUSION The depressed cellular function of EAL could be reversed with double signal stimulation, including IL-2 plus IL-7, IL-2 plus IL-12, or IL-2 plus TCR-CD3 engagement. These recovered cellular functions were mainly from CD8(+) CTL.

[1]  R. Perng,et al.  Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[2]  F. Salazar-Onfray Interleukin-10: a cytokine used by tumors to escape immunosurveillance , 1999, Medical oncology.

[3]  R. Coffman,et al.  The role of IL-4 and IL-10 cytokines in controlling an anti-tumor response in vivo. , 1998, International immunology.

[4]  W. Tsai,et al.  Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. , 1997, Chest.

[5]  J. Whang‐Peng,et al.  Restoration of the Immunocompetence by IL‐2 Activation and TCR‐CD3 Engagement of the In Vivo Anergized Tumor‐Specific CTL from Lung Cancer Patients , 1997, Journal of immunotherapy.

[6]  A. Mackensen,et al.  Immunostimulatory cytokines in somatic cells and gene therapy of cancer. , 1997, Cytokine & growth factor reviews.

[7]  J. Whang‐Peng,et al.  Elevation of interleukin-10 levels in malignant pleural effusion. , 1996, Chest.

[8]  E. Maxwell,et al.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism , 1996, The Journal of experimental medicine.

[9]  M. Gore,et al.  IL‐12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL) , 1996, Clinical and experimental immunology.

[10]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[11]  S. Sone,et al.  Interleukin‐10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages , 1994, Journal of leukocyte biology.

[12]  S. Rosenberg,et al.  Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy , 1991, The Journal of experimental medicine.

[13]  M. Alderson,et al.  Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood , 1990, The Journal of experimental medicine.

[14]  E. Reinherz,et al.  Monoclonal antibodies defining distinctive human T cell surface antigens. , 1979, Science.

[15]  H. Yamaue,et al.  The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor , 1992, Biotherapy.